Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.68 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.68 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8973477 | 0.98 | GNAI3 (0.71) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL8972105 | 0.98 | GNAI3 (0.71) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL3339374 | 0.98 | GNAI3 (0.71) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL8972364 | 0.98 | GNAI3 (0.71) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL8972071 | 0.98 | GNAI3 (0.71) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL4548016 | 0.98 | GNAI3 (0.71) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL31632756 | 0.98 | GNAI3 (0.71) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL8972852 | 0.98 | GNAI3 (0.71) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL8972731 | 0.98 | GNAI3 (0.71) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL8973186 | 0.98 | GNAI3 (0.71) | L3MBTL1MEN1KMT2ATDP1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023097251-A1 | OLIGONUCLEOTIDE-CONTAINING TRANSCRIPTION FACTOR TARGETING CHIMERAS | YALE UNIVERSITY (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-3660004-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021194879-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3778571-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | Bioway, Inc. (KR) | 2021-02-17 | — | — | EP | disclosed |
| EP-3660004-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-2294144-B1 | ANTIFOULING COMPOUNDS AND USE THEREOF | UNIV SINGAPORE (SG) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012162025-A1 | METHODS OF SELECTING CANCER PATIENTS FOR TREATMENT WITH N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110092518-A1 | Antifouling Compounds And Use Thereof | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2011-04-21 | — | — | US | disclosed |
| US-20110092518-A1 | Antifouling Compounds And Use Thereof | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2011-04-21 | — | — | US | disclosed |
| WO-2010138820-A2 | N,N-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2009139729-A1 | ANTIFOULING COMPOUNDS AND USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2009-11-19 | — | — | WO | disclosed |
| EP-0582065-A1 | 1-Oxohydrocarbyl-substituted azacyclohexanes compositions used as acid catalyst | WHITBY RESEARCH, Inc. (US) | 1994-02-09 | — | — | EP | disclosed |
| EP-0280703-B1 | COMPOSITIONS COMPRISING 1-ACYL-SUBSTITUTED MORPHOLINES, THIOMORPHOLINES AND PIPERAZINES AND THEIR USES | WHITBY RESEARCH INC (US) | 1993-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092518-A1 | Antifouling Compounds And Use Thereof | C5, C9, C1S | L3MBTL1 337/4885MEN1 1516/4885KMT2A 1564/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | L3MBTL1 2898/4885MEN1 1674/4885KMT2A 1463/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | L3MBTL1 4862/4885MEN1 4840/4885KMT2A 2718/4885 |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | NSUN2, EIF2AK2, RNGTT | L3MBTL1 462/4885MEN1 2936/4885KMT2A 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.